Results for tag: "Paragraph IV"

The Paragraph IV market is a segment of the generic drug industry that focuses on the development and sale of generic drugs that are protected by patents. These drugs are typically developed by generic drug manufacturers who challenge the patents of brand-name drugs in order to gain approval from the U.S. Food and Drug Administration (FDA) to market their generic versions. The process of challenging a patent is known as a Paragraph IV certification. The Paragraph IV market is a highly competitive industry, with many generic drug manufacturers vying for FDA approval. Companies in this market include Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. These companies are all major players in the generic drug industry, and have a strong presence in the Paragraph IV market. Show Less Read more